Ernexa Therapeutics 

Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions. Its primary therapeutic, ERNA-101, is an allogeneic iMSC specifically formulated to secrete pro-inflammatory cytokines like IL-7 and IL-15 for the treatment of ovarian cancer. Complementing this, ERNA-102 is another iMSC designed to deliver the anti-inflammatory cytokine IL-10, targeting rheumatoid arthritis. Ernexa Therapeutics has secured a licensing agreement with Factor Bioscience Limited. The company, founded in 2018 and headquartered in Cambridge, Massachusetts, was formerly named Eterna Therapeutics Inc., before officially changing to Ernexa Therapeutics in March 2025.